Active Stocks
Thu Mar 28 2024 14:29:24
  1. Tata Steel share price
  2. 156.40 2.32%
  1. ITC share price
  2. 432.80 1.12%
  1. HDFC Bank share price
  2. 1,456.05 1.07%
  1. Power Grid Corporation Of India share price
  2. 278.85 2.88%
  1. State Bank Of India share price
  2. 758.30 3.30%
Business News/ Companies / Ranbaxy loses bid to block rivals in generic drugs fight
BackBack

Ranbaxy loses bid to block rivals in generic drugs fight

Ranbaxy loses bid for a temporary court order to block rivals' generic versions of heartburn pill Nexium and antiviral drug Valcyte

Ranbaxy wanted the order to prevent competitors Dr. Reddy’s Laboratories Ltd and the US unit of Dublin-based Endo International from moving ahead with marketing their generic versions of the compounds while its complaint was heard. Photo: Pradeep Gaur/MintPremium
Ranbaxy wanted the order to prevent competitors Dr. Reddy’s Laboratories Ltd and the US unit of Dublin-based Endo International from moving ahead with marketing their generic versions of the compounds while its complaint was heard. Photo: Pradeep Gaur/Mint

Washington: Ranbaxy Laboratories Ltd lost a bid for a temporary court order to block rivals’ generic versions of the heartburn pill Nexium and the antiviral drug Valcyte.

Ranbaxy sought the order in a lawsuit against the US Food and Drug Administration (FDA) over the agency’s revocation of tentative approval for the company to make its own generic versions of the drugs.

The FDA revocation wrongfully punishes Ranbaxy for manufacturing deficiencies found at two Indian facilities in 2006 and 2008, blocking “hundreds of millions of dollars in anticipated revenue," the company said in a complaint filed on 14 November in federal court in Washington.

Ranbaxy, based in Gurgaon, wanted the order to prevent competitors Dr. Reddy’s Laboratories Ltd and the US unit of Dublin-based Endo International Plc from moving ahead with marketing their generic versions of the compounds while its complaint was heard.

US district judge Beryl Howell on Thursday declined to restrain Endo and Dr. Reddy’s and gave Ranbaxy and the FDA until 21 November to propose a schedule for further proceedings.

A Ranbaxy representative in Gurgaon didn’t immediately respond to an email before regular business hours seeking comment on the ruling. Bloomberg

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 20 Nov 2014, 10:04 AM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App

Chat with MintGenie